Institution
Charles University in Prague
Education•Prague, Czechia•
About: Charles University in Prague is a education organization based out in Prague, Czechia. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 32392 authors who have published 74435 publications receiving 1804208 citations.
Topics: Population, Large Hadron Collider, Czech, Magnetization, Transplantation
Papers published on a yearly basis
Papers
More filters
••
Imperial College London1, University of Missouri2, University of Glasgow3, European Bioinformatics Institute4, Wellcome Trust Centre for Human Genetics5, Medical College of Wisconsin6, University of Wisconsin-Madison7, Mayo Clinic8, Karolinska Institutet9, Max Delbrück Center for Molecular Medicine10, Kyoto University11, University of Iowa12, University of Edinburgh13, Academy of Sciences of the Czech Republic14, Charles University in Prague15, University of Nebraska Medical Center16, Université libre de Bruxelles17, Baylor College of Medicine18
TL;DR: This work outlines achievements in rat gene discovery to date, shows how these findings have been translated to human disease, and document an increasing pace of discovery of new disease genes, pathways and mechanisms.
Abstract: The rat is an important system for modeling human disease. Four years ago, the rich 150-year history of rat research was transformed by the sequencing of the rat genome, ushering in an era of exceptional opportunity for identifying genes and pathways underlying disease phenotypes. Genome-wide association studies in human populations have recently provided a direct approach for finding robust genetic associations in common diseases, but identifying the precise genes and their mechanisms of action remains problematic. In the context of significant progress in rat genomic resources over the past decade, we outline achievements in rat gene discovery to date, show how these findings have been translated to human disease, and document an increasing pace of discovery of new disease genes, pathways and mechanisms. Finally, we present a set of principles that justify continuing and strengthening genetic studies in the rat model, and further development of genomic infrastructure for rat research.
296 citations
••
TL;DR: The ADNEX model discriminates well between benign and malignant tumours and offers fair to excellent discrimination between four types of ovarian malignancy, which could improve triage and management decisions and so reduce morbidity and mortality associated with adnexal pathology.
Abstract: Objectives To develop a risk prediction model to preoperatively discriminate between benign, borderline, stage I invasive, stage II-IV invasive, and secondary metastatic ovarian tumours.
Design Observational diagnostic study using prospectively collected clinical and ultrasound data.
Setting 24 ultrasound centres in 10 countries.
Participants Women with an ovarian (including para-ovarian and tubal) mass and who underwent a standardised ultrasound examination before surgery. The model was developed on 3506 patients recruited between 1999 and 2007, temporally validated on 2403 patients recruited between 2009 and 2012, and then updated on all 5909 patients.
Main outcome measures Histological classification and surgical staging of the mass.
Results The Assessment of Different NEoplasias in the adneXa (ADNEX) model contains three clinical and six ultrasound predictors: age, serum CA-125 level, type of centre (oncology centres v other hospitals), maximum diameter of lesion, proportion of solid tissue, more than 10 cyst locules, number of papillary projections, acoustic shadows, and ascites. The area under the receiver operating characteristic curve (AUC) for the classic discrimination between benign and malignant tumours was 0.94 (0.93 to 0.95) on temporal validation. The AUC was 0.85 for benign versus borderline, 0.92 for benign versus stage I cancer, 0.99 for benign versus stage II-IV cancer, and 0.95 for benign versus secondary metastatic. AUCs between malignant subtypes varied between 0.71 and 0.95, with an AUC of 0.75 for borderline versus stage I cancer and 0.82 for stage II-IV versus secondary metastatic. Calibration curves showed that the estimated risks were accurate.
Conclusions The ADNEX model discriminates well between benign and malignant tumours and offers fair to excellent discrimination between four types of ovarian malignancy. The use of ADNEX has the potential to improve triage and management decisions and so reduce morbidity and mortality associated with adnexal pathology.
296 citations
••
University of Padua1, University of Würzburg2, University of Texas Southwestern Medical Center3, Hospital of the University of Pennsylvania4, University of Pennsylvania5, Radboud University Nijmegen6, University of Queensland7, University of Calgary8, Université de Montréal9, Medical College of Wisconsin10, Charité11, University of Düsseldorf12, Tohoku University13, Charles University in Prague14, National Taiwan University15
TL;DR: Despite carrying a minimal risk of adrenal vein rupture and at variance with the guidelines, AVS is not used systematically at major referral centers worldwide, representing an argument for defining guidelines for this clinically important but technically demanding procedure.
Abstract: Context: In patients who seek surgical cure of primary aldosteronism (PA), The Endocrine Society Guidelines recommend the use of adrenal vein sampling (AVS), which is invasive, technically challenging, difficult to interpret, and commonly held to be risky. Objective: The aim of this study was to determine the complication rate of AVS and the ways in which it is performed and interpreted at major referral centers. Design and Settings: The Adrenal Vein Sampling International Study is an observational, retrospective, multicenter study conducted at major referral centers for endocrine hypertension worldwide. Participants: Eligible centers were identified from those that had published on PA and/or AVS in the last decade. Main Outcome Measure: The protocols, interpretation, and costs of AVS were measured, as well as the rate of adrenal vein rupture and the rate of use of AVS. Results: Twenty of 24 eligible centers from Asia, Australia, North America, and Europe participated and provided information on 2604 AVS ...
295 citations
••
TL;DR: Despite the recommendations of national and international regulatory agencies, exclusion of older individuals from ongoing trials regarding heart failure continues to be widespread.
Abstract: Methods: In the context of the Increasing the PaRticipation of the ElDerly in Clinical Trials (PREDICT) study, data from ongoing clinical trials regarding heart failure were extracted from the World Health Organization Clinical Trials Registry Platform on December 1, 2008. Main outcome measures were the proportion of trials excluding patients by an arbitrary upper age limit or by other exclusion criteria that might indirectly cause limited recruitment of older individuals. We classified exclusion criteria into 2 categories: justified or poorly justified. Results: Among 251 trials investigating treatments for heart failure, 64 (25.5%) excluded patients by an arbitrary upper age limit. Such exclusion was significantly more common in trials conducted in the European Union than in the United States (31/96 [32.3%] vs 17/105 [16.2%];P=.007) and in drug trials sponsored by public institutions vs those by private entities (21/59 [35.6%] vs 5/36 [13.9%];P=.02). Overall, 109 trials (43.4%) on heart failure had 1 or more poorly justified exclusion criteria that could limit the inclusion of older individuals. A similar proportion of clinical trials with poorly justified exclusion criteria was found in pharmacologic and nonpharmacologic trials. Conclusion: Despite the recommendations of national and international regulatory agencies, exclusion of older individuals from ongoing trials regarding heart failure continues to be widespread.
295 citations
••
TL;DR: In this article, a conceptual framework for interpreting the process of urban change in post-communist cities is developed, where the departure from the legacies of the communist past has been effected through mul...
Abstract: This paper develops a conceptual framework for interpreting the process of urban change in post-communist cities. The departure from the legacies of the communist past has been effected through mul...
295 citations
Authors
Showing all 32719 results
Name | H-index | Papers | Citations |
---|---|---|---|
Ronald C. Petersen | 178 | 1091 | 153067 |
P. Chang | 170 | 2154 | 151783 |
Vaclav Vrba | 141 | 1298 | 95671 |
Milos Lokajicek | 139 | 1511 | 98888 |
Christopher D. Manning | 138 | 499 | 147595 |
Yves Sirois | 137 | 1334 | 95714 |
Rupert Leitner | 136 | 1201 | 90597 |
Gerald M. Reaven | 133 | 799 | 80351 |
Roberto Sacchi | 132 | 1186 | 89012 |
S. Errede | 132 | 1481 | 98663 |
Mark Neubauer | 131 | 1252 | 89004 |
Peter Kodys | 131 | 1262 | 85267 |
Panos A Razis | 130 | 1287 | 90704 |
Vit Vorobel | 130 | 919 | 79444 |
Jehad Mousa | 130 | 1226 | 86564 |